Peter Smith, Ph.D.

Peter Smith, Ph.D. has an extensive work experience in the biopharmaceutical industry. Peter is currently serving as the Chief Scientific Officer at ReNAgade Therapeutics since June 2021. Prior to this, they worked at Alnylam Pharmaceuticals from 2017 to 2021, where they held the roles of Chief Early Development Officer and Senior Vice President. In these positions, they oversaw all aspects of Non Clinical Development and Investigative Sciences, including drug safety, DMPK, regulatory support, and investigative sciences related to drug mechanisms.

Before joining Alnylam Pharmaceuticals, Dr. Smith worked at Moderna Therapeutics from 2014 to 2017 as the Senior Vice President of R&D Non Clinical. Peter also has experience as a consultant in drug discovery and development in 2013 and as the Senior Vice President at Millennium Pharmaceuticals from 2001 to 2013. In their role at Millennium Pharmaceuticals, they were responsible for overseeing R&D, including non-clinical aspects of drug discovery and development and leadership of pharmaceutical sciences. Additionally, they held the position of Senior Vice President, Non Clinical at Millennium: The Takeda Oncology Company during the same period.

Peter Smith, Ph.D. began their higher education journey in 1975 at Fairfield University, where they pursued a Bachelor of Science (B.S.) degree in Biology/Biological Sciences. Peter successfully completed their undergraduate studies in 1979. Subsequently, they joined the University of Arizona in 1981 to further their academic pursuits. At the University of Arizona, they delved into the field of Pharmacology and Toxicology, and after four years of rigorous study, they obtained their Ph.D. in 1985.